Business Insider3d
Shanghai Henlius Biotech to Vote on Major Merger
Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update. Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter ...
GlobalData on MSN5d
Palleon and Shanghai Henlius Biotech link on autoimmune therapy
Palleon Pharmaceuticals and Shanghai Henlius Biotech have entered a licence agreement and partnership for the former’s ...
Business Insider3d
Shanghai Henlius Biotech Moves Toward Privatization
Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update. Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter ...
Hosted on MSN3d
Shanghai Fosun Pharmaceutical Advances Henlius Merger Plans
Shanghai Fosun Pharmaceutical is moving forward with the proposed privatization of Shanghai Henlius Biotech through a merger by absorption. The company has dispatched a composite ...
Hosted on MSN19d
Shanghai Henlius Biotech Advances in Cancer Treatment
Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update. Shanghai Henlius Biotech, Inc. has received approval from China’s National Medical Products Administration to initiate ...
Nasdaq21d
Shanghai Henlius Biotech Advances in HER2 Therapy Trial
Shanghai Henlius Biotech, Inc. has received approval from the National Medical Products Administration for a phase 2 clinical trial of its innovative anti-HER2 monoclonal antibody, HLX22 ...
Yahoo Finance6d
High Growth Tech Stocks Including Shanghai Henlius Biotech
Overview: Shanghai Henlius Biotech, Inc. focuses on the research and development of biologic medicines targeting oncology, autoimmune diseases, and ophthalmic diseases, with a market cap of HK$12. ...
Shanghai Henlius Biotech Announces Merger Vote
Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update.Don't Miss Our Christmas Offers:Discover the latest stocks recommended ...